Evidence map›Paper›PMID 31939052›Full record

ArticleMycopathologia2020

Breakthrough Invasive Fungal Infections in Patients with Acute Myeloid Leukemia.

Anastasia Wasylyshyn, Kathleen A Linder, Caroline G Castillo, Shiwei Zhou, Carol A Kauffman, Marisa H Miceli

Abstract read
PubMed Publisher
In one paragraph

Article in Mycopathologia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.3field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. InvasiveInfection and drug resistance · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Invasive Fungal Infections 2021.Journal of fungi (Basel, Switzerland) · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. First Reported Case of Invasive CutaneousOpen forum infectious diseases · 2021
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Anastasia WasylyshynDivision of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Kathleen A LinderDivision of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Caroline G CastilloDivision of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Shiwei ZhouDivision of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Carol A KauffmanDivision of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Marisa H MiceliDivision of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. mmiceli@med.umich.edu.
University of Michigan–Ann Arbor · USMichigan Medicine · USVA Ann Arbor Healthcare System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWe sought to determine the occurrence, risk factors, effect of antifungal prophylaxis, and outcomes of invasive fungal infections (IFIs) in patients with acute myeloid leukemia (AML). PATIENTS AND

methodsWe performed a retrospective analysis of all adult patients admitted to the University of Michigan Health System for AML over a 3-year period from 2010 to 2013. We determined comorbidities, hematopoietic cell transplant (HCT) status, antifungal prophylaxis, proven and probable IFI, and outcomes at 12 weeks after initiation of appropriate antifungal therapy.

resultsOf 333 patients in our cohort, 116 of whom had received a HCT, 98 (29%) developed an IFI. Of the 30 (9%) patients who had a proven or probable IFI, 18 had breakthrough infection while on micafungin (n = 5), voriconazole (n = 4), posaconazole (n = 5), or fluconazole (n = 4). Breakthrough IFIs were due to Aspergillus species (n = 11), other molds (n = 4), and Candida species (n = 3). Factors associated with breakthrough IFI were prolonged severe neutropenia (p = .05) and having received tacrolimus (p = .04). Antifungal therapy was successful in 7 of the 18 (39%) patients with breakthrough IFI and 8 of the 12 (67%) patients with non-breakthrough IFI, p = .13. Mortality at 12 weeks was 27%, 5 with breakthrough IFI and 3 with non-breakthrough IFI and was associated with prolonged severe neutropenia, p = .04.

conclusionsPatients with AML remain at risk for IFI despite the use of several different antifungal agents for prophylaxis. Mortality remains high in patients with AML who develop IFI.

Indexed as

Invasive Fungal InfectionsAdultAgedAntifungal AgentsAspergillusCandidaCohort StudiesFemaleHumansImmunosuppressive AgentsLeukemia, Myeloid, AcuteMaleMiddle AgedMortalityNeutropeniaRetrospective StudiesAntifungal AgentsImmunosuppressive AgentsTacrolimusAcute leukemiaAntifungal prophylaxisAspergillosisBreakthrough invasive fungal infectionsMold infections

Identifiers

PMID31939052
OpenAlexW3000385729

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.